- Home
- OFIX vs AVIR Comparison
OFIX vs AVIR Comparison
Compare OFIX & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OFIX | AVIR |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.0M | 429.1M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OFIX | AVIR |
|---|---|---|
| Price | $8.89 | $5.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $13.00 | $9.42 |
| AVG Volume (30 Days) | ★ 381.3K | 273.8K |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.39 | 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $822,312,000.00 | $351,367,000.00 |
| Revenue This Year | $3.48 | N/A |
| Revenue Next Year | $2.46 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $8.50 | $2.87 |
| 52 Week High | $16.99 | $6.45 |
Technical Indicators
Market Signals| Indicator | OFIX | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 41.60 | 49.11 |
| Support Level | $8.68 | $5.01 |
| Resistance Level | $9.92 | $5.76 |
| Average True Range (ATR) | 0.42 | 0.22 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 30.03 | 38.93 |
Price Performance
Historical ComparisonAbout OFIX Orthofix Medical Inc. (DE)
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.